167479-13-2

Basic information

• Product Name: 4-Bromoindole-2-carboxylic acid methyl ester
• Synonyms: 4-Bromoindole-2-carboxylic acid methyl ester;1H-Indole-2-carboxylic acid, 4-broMo-, Methyl ester;4-bromo-1H-indole-2-carboxylic acid methyl ester;Methyl 4-bromoindole-2-carboxylate
• CAS NO: 167479-13-2
• Molecular Formula: C₁₀H₈BrNO₂
• Molecular Weight: 254.09
• Mol File: 167479-13-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 386.2 °C at 760 mmHg
• Flash Point: 187.3 °C
• Appearance: /
• Density: 1.629 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.04±0.30(Predicted)
• CAS DataBase Reference: 4-Bromoindole-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromoindole-2-carboxylic acid methyl ester(167479-13-2)
• EPA Substance Registry System: 4-Bromoindole-2-carboxylic acid methyl ester(167479-13-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 167479-13-2(Hazardous Substances Data)

Usage

General Description

4-Bromoindole-2-carboxylic acid methyl ester is a chemical compound that belongs to the indole family. It is a methyl ester derivative of 4-bromoindole-2-carboxylic acid, and its chemical formula is C10H8BrNO2. 4-Bromoindole-2-carboxylic acid methyl ester is commonly used in the synthesis of various pharmaceuticals and organic compounds. It has been studied for its potential pharmacological properties and biological activities. 4-Bromoindole-2-carboxylic acid methyl ester is a valuable building block in organic synthesis and has applications in medicinal chemistry and drug discovery. Its unique structure and reactivity make it a versatile and important chemical in the field of organic chemistry.

Upstream product

• 16732-64-2 4-bromo-1H-indole-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 52488-36-5 4-bromo-1H-indole 
• 558-13-4 carbon tetrabromide 
• 6630-33-7 ortho-bromobenzaldehyde 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 220448-44-2 C₁₀H₈BrN₃O₂ 

Downstream Products

• 1079252-75-7 methyl 4-bromo-3-formyl-1H-indole-2-carboxylate 
• 1362861-01-5 methyl 4-(4-methoxyphenyl)-1H-indole-2-carboxylate 
• 1362861-28-6 11-(4-hydroxyphenyl)chromeno[3,4-b]indole-6(7H)-one 
• 1362861-29-7 2-hydroxy-11-(4-hydroxyphenyl)chromeno[3,4-b]indole-6(7H)-one 
• 1362861-03-7 methyl 3-iodo-4-(4-methoxyphenyl)-1H-indole-2-carboxylate 
• 1362861-10-6 methyl 3-(2-methoxyphenyl)-4-(4-methoxyphenyl)-1H-indole-2-carboxylate 
• 1362861-11-7 methyl 3-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)-1H-indole-2-carboxylate 
• 1446308-69-5 C₁₆H₁₄BrNO₃S 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

A Bu4N[Fe(CO)3(NO)]-Catalyzed Hemetsberger–Knittel Indole Synthesis

The nucleophilic Fe complex Bu4N[Fe(CO)3(NO)] (TBA[Fe]) catalyzes the direct intramolecular amination of aryl vinyl azides to give the corresponding indole derivatives in good to excellent yields.

Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: A novel DYRK1A inhibitor class

A library of substituted chromeno[3,4-b]indoles was developed as Lamellarin isosters. Synthesis was achieved from indoles after a four-step pathway sequence involving C-3 iodination, a Suzuki cross-coupling reaction, and a one pot deprotection/lactonisation step. Twenty final compounds were tested in order to determine their activity against topoisomerase I and kinases, the two major biological activities of Lamellarins. One newly synthesized derivative exhibited a strong topoisomerase activity comparable to reference compounds such as campthotecin and Lamellarin with only a weak kinase inhibition. Two other lead compounds were identified as new nanomolar DYRK1A inhibitors and several other drugs affected the kinases in the sub-micromolar range. These results will enable us to use the chromeno[3,4-b]indole as a pharmacophore to develop potent treatments for neurological or oncological disorders in which DYRK1A is fully involved.